Burger Recall Update as FDA Sets Highest Risk Level
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A recall of seafood burgers has been issued a Class I risk classification by the U.S. Food and Drug Administration (FDA).
The recall was initiated earlier this month by the Connecticut based company Caraluzzi's Markets due to the undeclared presence of egg, a major food allergen.
Newsweek has contacted Caraluzzi's Markets for comment outside of regular working hours.
Caraluzzi's Markets initiated a voluntary recall of its Italian-style seafood burgers earlier this month due to the undeclared presence of egg.
Caraluzzi's Markets initiated a voluntary recall of its Italian-style seafood burgers earlier this month due to the undeclared presence of egg.
Caraluzzi's Markets
Why It Matters
Eggs are one of the nine major food allergens, as defined in law. The others include milk, fish, shellfish, tree nuts, peanuts, wheat, soybeans, and sesame.
Egg allergies are common and in rare cases can lead to anaphylaxis — a severe and potentially fatal reaction. When an allergen is not properly listed on food packaging, it puts unsuspecting consumers at risk.
For those who are sensitive to any of these foods, they can have a reaction within minutes or hours, and symptoms can range from mild to life-threatening.
What To Know
Caraluzzi's Markets initiated a recall on April 8 for its eight-ounce Italian Style Seafood Burgers because the packaging did not reveal the presence of egg.
The affected product was distributed and sold between February 18 and April 2, 2025, at Caraluzzi's Markets locations in Bethel, Wilton, Newtown, and Danbury. Connecticut is the only state affected by the recall, according to the FDA report.
The burgers that were part of the recall had an expiration date of January 16, 2026, with the UPC code 0-95864-80008-8.
The FDA issued its Class I classification on April 30, meaning it is a "situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death."
The labeling error came to light following a consumer complaint that prompted an internal investigation by Caraluzzi's Markets.
As of April 8, one allergic reaction had been reported. It is not clear if any other allergic reactions have occurred.
The mislabeled burgers have been removed from store shelves, but the recall is ongoing, according to the FDA.
What People Are Saying
Dr. Sebastian Lighvani, the director of New York Allergy & Asthma PLLC, told Newsweek previously: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last 5, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods."
What Happens Next
Customers who purchased the product are urged not to eat it and to return it to the place of purchase for a full refund.
Consumers with questions about the recall are encouraged to contact Caraluzzi's Markets at 203-748-3547, via email at customerservice@caraluzzis.com, or in person at any store customer service desk.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
FDA Pauses Trials of Gilead HIV Combination After Safety Signal
Gilead Sciences Inc. said federal regulators had placed on hold trials of a new experimental once-weekly HIV drug combination therapy after white blood cell counts dropped in some of the patients. The studies were testing two experimental HIV drugs, GS-1720 and GS-4182, when given together. Gilead said the Food and Drug Administration paused the trials due to a ' safety signal ' triggered by a decrease in lymphocyte levels in some patients given the therapy. Lymphocytes are a type of white blood cell that play a critical role in the immune system's ability to fight infections.
Medscape
an hour ago
- Medscape
Insmed's Drug for Rare Lung Disease Meets Main Goal in Mid-stage Trial
(Reuters) -Insmed said on Tuesday that its experimental drug significantly reduced blood pressure in the lungs and improved exercise capacity in patients in a mid-stage study, sending shares of the company up 26% in premarket trading. The drug, treprostinil palmitil, is a once-daily therapy that is inhaled through a device. The 102-patient study found that the drug helped reduce blood pressure in the patients' lungs by 35%, compared with a placebo. It also helped improve the patients' ability to walk by an average of 35.5 meters and reduced levels of a protein associated with heart stress by 60%. The company plans to discuss the trial data with the U.S. Food and Drug Administration and initiate a late-stage trial for the drug in patients with pulmonary arterial hypertension (PAH) — a rare disease caused by a constriction of arteries in the lungs, leading to high blood pressure - in early 2026. Insmed also plans to start a separate late-stage trial for the drug in patients with pulmonary hypertension associated with interstitial lung disease - a condition where lung scarring leads to high blood pressure in the lung arteries - before the end of 2025. Current treatment options available to treat PAH are Merck's injectable Winrevair and Liquidia's inhaled Yutrepia. (Reporting by Kamal Choudhury in Bengaluru; Editing by Maju Samuel) Reuters Health Information © 2025 Reuters Ltd.
Newsweek
an hour ago
- Newsweek
Honey Recall Map Shows Warnings Issued to Customers in 7 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Food and Drug Administration (FDA) has announced its classification of a recall of certain Comvita honey products, affecting seven states. Comvita, a California-based company, recalled three of its manuka honey products last month as the induction seal was not properly fitted, meaning the product was leaking on the packaging. Newsweek has contacted Comvita outside of regular working hours via email for comment. File photo: a teaspoon with a jar full of honey. File photo: a teaspoon with a jar full of honey. Oliver Berg/dpa via AP Why It Matters Maintaining packaging standards is important as it can make consumers feel more assured that companies have followed regulatory guidance more closely, and ensured their products are properly manufactured and controlled. Given that many Americans are concerned about food safety and food recalls, maintaining standards and regulations are even more important if brands want to establish consumer trust. What To Know The affected products include: Comvita's Manuka Honey + Lion's Mane for Focus (355g), with lot codes 34828522 and 34835584, and expiration dates of January 21, 2026 and February 21, 2026 respectively Comvita's Manuka Honey + Cordyceps for Energy (355g) with lot codes 34828523 and 34835585, and expiration dates of January 22, 2026 and February 25, 2026 respectively Comvita's Manuka Honey + Reishi (355g) with lot codes 34828521 and 34835574, and expiration dates of January 21, 2026 and February 24, 2026 respectively There were 2,730 units sold of each product, to various states including Colorado, Arizona, Texas, Maryland, Florida, California, and Georgia. Comvita initiated the recall on May 23, and the FDA announced its classification of the recall on June 9. The FDA classification of the recall was a Class II, meaning it is a situation "in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." What People Are Saying Professor Byron Chaves, a professor and food safety extension specialist in the department of Food Science and Technology at the University of Nebraska-Lincoln, told Newsweek: "An induction seal is a protective seal commonly found on food containers, like jars or bottles, just under the cap. It's created using heat to attach a foil liner to the container's opening, forming a tight, tamper-evident seal. This helps prevent leaks, keeps the product fresh, and shows if the package has been opened." He added: "If an induction seal isn't properly applied, it can lead to leaks, contamination, and reduced shelf life. It also means the package may not show evident signs of tampering, which can raise safety concerns. In some cases, it could lead to regulatory issues or loss of consumer trust if the product appears unsafe or poorly sealed." What Happens Next Consumers are advised not to consume the affected products and return them to the place of purchase for a refund. As of June 9, the recall remains ongoing. The FDA did not specify if any illnesses had been reported in relation to the recall.
